AKT1 and non-small cell lung carcinoma: In non-small-cell lung cancer (NSCLC), LINC00665 knockdown inhibits the proliferation and restores gefitinib sensitivity via the regulation of EZH2 and PI3K/AKT signaling pathway [29].